Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Single-Cell Multi-Omics Analysis Reveals Autologous Stem Cell Chemo-Mobilization with Etoposide +Cytarabine Plus G-CSF in Multiple Myeloma

Zhijuan Zhu, Jiali Zhu, Xiaofan Li, Ming Zhu, Jinxian Dai, Jialiang Huang, Nainong Li

Blood (2024) 144 (Supplement 1): 7111.

https://doi.org/10.1182/blood-2024-201933

Published: 2024

Journal Articles

Single-Cell Multi-Omics Reveals Immune Characteristics of T Cells in Patients with Relapsed/Refractory Leukemia after Haplo+Cord HSCT

Nainong Li, Hua Li, Zheyang Zhang, Ming Zhu, Xiaofan Li, Ping Chen, Fei Chen, Xianling Chen, Yiding Yang, Xiaohong Yuan, Ronghan Tang, Zhijuan Zhu, Hongli Lin, Ting Lin, Mengsha Tong, Tao Chen, Chen Zhong, Jialiang Huang

Blood (2024) 144 (Supplement 1): 7110.

https://doi.org/10.1182/blood-2024-207216

Published: 2024

Journal Articles

A Multicenter Prospective Clinical Study of Venetoclax Combined with Azactidine in the Treatment of Newly Diagnosed Acute Leukaemias of Ambiguous Lineage: Interim Analysis of a Phase 2 Trial

Si-Man Huang, Tong-Tong Zhang, Lan Dai, Chao-Ling Wan, Han-Yu Cao, Hai-Ping Dai, Ming-Zhu Xu, Depei Wu, Sheng-Li Xue

Blood (2024) 144 (Supplement 1): 5899.

https://doi.org/10.1182/blood-2024-204660

Published: 2024

Journal Articles

Orelabrutinib Plus R-CHOP Regimen in Treatment-Naïve Patients with TP53-Mutated Diffuse Large B-Cell Lymphoma (DLBCL)

Yi Xiao, Jiaying Wu, Mi Zhou, Zhen Shang, Ming Zhu

Blood (2023) 142 (Supplement 1): 6289.

https://doi.org/10.1182/blood-2023-177563

Published: 2023

Journal Articles

Safety and Efficacy of CD22/ CD19 CAR-T and Auto-HSCT “Sandwich” Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia

Yan Qiu, Chong-Sheng Qian, Hai-Xia Zhou, Ming-Zhu Xu, Li-Qing Kang, Ai-Ning Sun, De-Pei Wu, Lei Yu, Sheng-Li Xue

Blood (2023) 142 (Supplement 1): 3481.

https://doi.org/10.1182/blood-2023-182728

Published: 2023

Journal Articles

Venetoclax, Cladribine and Cytarabine for the Treatment of Relapse/Refractory Acute Lymphoblastic Leukemia: Interim Analysis of a Phase 2 Trial

Yan-yan Li, Hai-xia Zhou, Si-man Huang, Chao-Ling Wan, Ming-zhu Xu, Wen-jie Gong, Chong-Sheng Qian, De-pei Wu, Haiping Dai, Sheng-Li Xue

Blood (2023) 142 (Supplement 1): 1506.

https://doi.org/10.1182/blood-2023-185312

Published: 2023

Journal Articles

Single-Cell Multi-Omics Analysis Reveals the Role of CX3CR1 + GNLY + CD8 + T Cells in Improving Survival of Patients with Relapse/Refractory Hematologic Malignancies after Haplo+Cord HSCT

Hua Li, Zheyang Zhang, Ming Zhu, Xiaofan Li, Tao Chen, Yuanzhong Chen, Jialiang Huang, Nainong Li

Blood (2022) 140 (Supplement 1): 7349.

https://doi.org/10.1182/blood-2022-157757

Published: 2022

Journal Articles

Safety and Efficacy of CD22 and CD19 Chimeric Antigen Receptor T Cell Treatment Bridging to Autologous Stem Cell Transplantation As Consolidation Therapy for B-Cell Acute Lymphoblastic Leukemia

Yan Qiu, Chong-Sheng Qian, Hai-Xia Zhou, Ming-Zhu Xu, Li-Qing Kang, Ai-Ning Sun, De-Pei Wu, Lei Yu, Shengli Xue

Blood (2022) 140 (Supplement 1): 10337–10338.

https://doi.org/10.1182/blood-2022-164636

Published: 2022

Journal Articles

Correlative Biomarkers of Response to Venetoclax in Combination with Chemotherapy or Hypomethylating Agents in Elderly Untreated Patients with Acute Myeloid Leukemia

Brenda Chyla, Relja Popovic, Jalaja Potluri, John Hayslip, Xin Huang, Ming Zhu, Mack Mabry, Anahita Bhathena

Blood (2016) 128 (22): 1709.

https://doi.org/10.1182/blood.V128.22.1709.1709

Published: 2016

Journal Articles

Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia

Andrew Wei, Stephen A. Strickland, Gail J. Roboz, Jing-Zhou Hou, Walter Fiedler, MD, Tara L. Lin, Giovanni Martinelli, Roland B. Walter, MD PhD, Anoop Enjeti, Kaffa Fakouhi, David E. Darden, Martin Dunbar, Ming Zhu, Suresh Agarwal, Ahmed H. Salem, Mack Mabry, John Hayslip

Blood (2016) 128 (22): 102.

https://doi.org/10.1182/blood.V128.22.102.102

Published: 2016

Journal Articles

Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Andrew W. Roberts, John F Seymour, Barbara Eichhorst, MD, Stephan Stilgenbauer, Michael Y. Choi, MD, Matthew S. Davids, John F. Gerecitano, Relja Popovic, Brenda Chyla, Ming Zhu, Maria Verdugo, Jalaja Potluri, Leanne Lash, Su Young Kim, Michael Hallek

Blood (2016) 128 (22): 3230.

https://doi.org/10.1182/blood.V128.22.3230.3230

Published: 2016

Journal Articles

Detailed Safety Analysis of Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Danielle M. Brander, MD, Michael Y. Choi, MD, Andrew W. Roberts, Shuo Ma, L. Leanne Lash, Maria Verdugo, Ming Zhu, Su Young Kim, John F Seymour

Blood (2016) 128 (22): 2033.

https://doi.org/10.1182/blood.V128.22.2033.2033

Published: 2016

Journal Articles

Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib

Jeffrey Jones, Michael Y. Choi, MD, Anthony R. Mato, Richard R. Furman, Matthew S. Davids, Leonard T. Heffner, MD, Bruce D. Cheson, Nicole Lamanna, MD, Paul M. Barr, Herbert Eradat, Ahmad Halwani, Brenda Chyla, Ming Zhu, Maria Verdugo, Rod A. Humerickhouse, MD, Jalaja Potluri, William G. Wierda, MD PhD, Steven E. Coutre, MD

Blood (2016) 128 (22): 637.

https://doi.org/10.1182/blood.V128.22.637.637

Published: 2016

Journal Articles

A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

John F. Gerecitano, MD, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD, William G. Wierda, MD, Brad S. Kahl, MD, John M. Pagel, MD PhD, Soham Puvvada, MD, Thomas J. Kipps, MD PhD, Mary Ann Anderson, MBBS, Martin Dunbar, DrPH, Ming Zhu, PhD, Lori Gressick, BS, Lindsay Wagner, BS, Su Young Kim, MD, Sari Heitner Enschende, MD, Rod A. Humerickhouse, MD PhD, Matthew S. Davids, MD

Blood (2015) 126 (23): 254.

https://doi.org/10.1182/blood.V126.23.254.254

Published: 2015

Journal Articles

A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

Sven de Vos, MD PhD, Lode Swinnen, MD, Mark Kozloff, MD, Ding Wang, MD PhD, Erin Reid, MD, Loretta Nastoupil, MD, Nathan Fowler, MD, Jaclyn Cordero, Diane D'Amico, Susan Diehl, Martin Dunbar, DrPH, Ming Zhu, PhD, Shekman Wong, PhD, Sari Heitner Enschede, MD, David Chien, MD, Rod A. Humerickhouse, MD PhD, Christopher Flowers, MD

Blood (2015) 126 (23): 255.

https://doi.org/10.1182/blood.V126.23.255.255

Published: 2015

Journal Articles

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results

Blood (2015) 126 (23): 4219.

https://doi.org/10.1182/blood.V126.23.4219.4219

Published: 2015

Journal Articles

Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study

Blood (2015) 126 (23): LBA-6.

https://doi.org/10.1182/blood.V126.23.LBA-6.LBA-6

Published: 2015

Journal Articles

Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy

Jeffrey Jones, MD, Anthony R. Mato, MD, Steven Coutre, MD, William Wierda, MD PhD, Michael Y. Choi, MD, Matthew S. Davids, MD, Nicole Lamanna, MD, Paul Barr, MD, Kim Burns, BA, Nicholas Montalvo, MBA, Ming Zhu, PhD, Todd Busman, MS, Jalaja Potluri, MD FACP, Rod A. Humerickhouse, MD PhD, John C. Byrd, MD

Blood (2015) 126 (23): 715.

https://doi.org/10.1182/blood.V126.23.715.715

Published: 2015

Journal Articles

A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy

Courtney DiNardo, MD, Daniel Pollyea, MD MS, Keith Pratz, MD, Michael J. Thirman, MD, Anthony Letai, MD PhD, Mark Frattini, MD PhD, Brian Jonas, MDPhD, Joel Leverson, PhD, Ming Zhu, PhD, Martin Dunbar, DrPH, Nancy Falotico, Rachel Kirby, BA, Suresh Agarwal, PhD, Mack Mabry, MD, Jalaja Potluri, MD, Rod A. Humerickhouse, MD PhD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD

Blood (2015) 126 (23): 327.

https://doi.org/10.1182/blood.V126.23.327.327

Published: 2015

Journal Articles

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results

Philippe Moreau, MD PhD, Asher Chanan-Khan, MD, Andrew W. Roberts, MBBS, PhD, Amit B. Agarwal, MDPhD, Thierry Facon, Shaji Kumar, MD, Cyrille Touzeau, MD, David Darden, MS, Lura Morris, BA, Jeremy Ross, PhD, Ahmed H Salem, PhD, Wijith Munasinghe, PhD, Ming Zhu, PhD, Joel Leverson, PhD, Paulo Maciag, MD, Sari Heitner Enschede, MD, Maria Verdugo, MD, Rod A. Humerickhouse, MD PhD, Simon Harrison, MD

Blood (2015) 126 (23): 3038.

https://doi.org/10.1182/blood.V126.23.3038.3038

Published: 2015

NARROW

Single-Cell Multi-Omics Analysis Reveals Autologous Stem Cell Chemo-Mobilization with Etoposide +Cytarabine Plus G-CSF in Multiple Myeloma

Single-Cell Multi-Omics Reveals Immune Characteristics of T Cells in Patients with Relapsed/Refractory Leukemia after Haplo+Cord HSCT

A Multicenter Prospective Clinical Study of Venetoclax Combined with Azactidine in the Treatment of Newly Diagnosed Acute Leukaemias of Ambiguous Lineage: Interim Analysis of a Phase 2 Trial

Orelabrutinib Plus R-CHOP Regimen in Treatment-Naïve Patients with TP53-Mutated Diffuse Large B-Cell Lymphoma (DLBCL)

Safety and Efficacy of CD22/ CD19 CAR-T and Auto-HSCT “Sandwich” Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia

Venetoclax, Cladribine and Cytarabine for the Treatment of Relapse/Refractory Acute Lymphoblastic Leukemia: Interim Analysis of a Phase 2 Trial

Single-Cell Multi-Omics Analysis Reveals the Role of CX3CR1 + GNLY + CD8 + T Cells in Improving Survival of Patients with Relapse/Refractory Hematologic Malignancies after Haplo+Cord HSCT

Safety and Efficacy of CD22 and CD19 Chimeric Antigen Receptor T Cell Treatment Bridging to Autologous Stem Cell Transplantation As Consolidation Therapy for B-Cell Acute Lymphoblastic Leukemia

Correlative Biomarkers of Response to Venetoclax in Combination with Chemotherapy or Hypomethylating Agents in Elderly Untreated Patients with Acute Myeloid Leukemia

Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia

Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Detailed Safety Analysis of Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib

A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results

Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study

Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy

A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only